ReviewTranslational cancer research2019
Could cell division cycle protein 42 be a target for lung cancer treatment?
Review in Translational cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Discovery of CDC42 Inhibitors with a Favorable Pharmacokinetic Profile and Anticancer In Vivo Efficacy.Journal of medicinal chemistry · 2024Article
- Norcycloartocarpin targets Akt and suppresses Akt-dependent survival and epithelial-mesenchymal transition in lung cancer cells.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell division cycle protein 42 (Cdc42), a member of the Rho GTPase family, which is part of the Ras superfamily, plays important roles in multiple fundamental cellular processes. Deregulation of Cdc42 may cause cellular defects that are responsible for the activation of signaling pathways, and such deregulation is related to cancer formation. Lung cancer is one of the most devastating diseases worldwide. Cdc42 is overexpressed in human lung cancer samples, which suggests that this protein is associated with lung carcinogenesis. Herein, we review the functions of Cdc42 in lung cancer and discuss potential pharmacological approaches that target Cdc42 in cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.